Aa Aa Aa
  • News Releases

Keyword Search
 

DateTitlePrint
10/24/14Sucampo Pharmaceuticals, Inc. Announces Third Quarter 2014 Earnings CallPrinter Friendly Version
10/23/14Sucampo Solidifies Leadership Team With Additions of CSO and Heads of Business Development, Regulatory AffairsPrinter Friendly Version
10/21/14Takeda and Sucampo Enter Into Global Licensing Agreement for AMITIZA(R) (lubiprostone)Printer Friendly Version
10/14/14Sucampo Announces Extension of AMITIZA(R) (lubiprostone) License and Collaboration Agreement With TakedaPrinter Friendly Version
10/13/14Clinical Data for AMITIZA(R) Lubiprostone to be Presented at the American College of Gastroenterology 2014 Annual Scientific MeetingPrinter Friendly Version
10/09/14Sucampo Announces Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZAPrinter Friendly Version
10/06/14Sucampo Announces Departure of Chief Financial OfficerPrinter Friendly Version
09/29/14Sucampo and Takeda Launch Direct-to-Consumer Advertising Campaign for AMITIZA(R) (lubiprostone) for Chronic Idiopathic ConstipationPrinter Friendly Version
08/21/14Sucampo Announces New Exclusive Global Manufacturing and Supply Agreement for LubiprostonePrinter Friendly Version
08/05/14Sucampo Reports Second Quarter 2014 Financial Results and Corporate UpdatePrinter Friendly Version
07/23/14Sucampo Announces Publication of NICE Recommendation for AMITIZA(R) (Lubiprostone)Printer Friendly Version
07/22/14Sucampo Pharmaceuticals, Inc. Announces Second Quarter 2014 Financial Results and Corporate Update Teleconference and Webcast on August 5Printer Friendly Version
07/07/14Swissmedic Approves AMITIZA(R) (Lubiprostone) for the Treatment of Opioid-Induced ConstipationPrinter Friendly Version
06/17/14AMITIZA(R) (Lubiprostone) Receives NICE RecommendationPrinter Friendly Version
06/12/14Sucampo Issues Statement Regarding Anesthetic and Analgesic Drug Products Advisory Committee Meeting's VotePrinter Friendly Version
05/29/14Sucampo Announces Webcast of Its Presentation at 2014 Jefferies Global Healthcare ConferencePrinter Friendly Version
05/13/14Sucampo Announces Webcast of Its Presentation at the 2014 UBS Global Healthcare ConferencePrinter Friendly Version
05/07/14Sucampo Pharmaceuticals, Inc., Reports First Quarter 2014 Financial and Operating ResultsPrinter Friendly Version
05/06/14Sucampo Announces New Data on AMITIZA and Opioid-Induced Constipation Published Online in Pain Medicine JournalPrinter Friendly Version
05/01/14Sucampo Announces Clinical Data on Lubiprostone to be Presented at Two Upcoming Scientific ConferencesPrinter Friendly Version
04/30/14Sucampo Pharmaceuticals Announces First Quarter 2014 Results and Operating Highlights Teleconference and WebcastPrinter Friendly Version
04/25/14Preclinical Data for Lubiprostone and Unoprostone Isopropyl to be Presented at Experimental Biology Conference 2014Printer Friendly Version
03/25/14Sucampo Co-Founder and Chairman Emeritus, Dr. Ryuji Ueno, to Receive Visionary Award From the Foundation Fighting BlindnessPrinter Friendly Version
03/14/14Sucampo and Takeda Announce Update on Liquid Formulation Program for AMITIZA(R) (lubiprostone)Printer Friendly Version
03/12/14Sucampo Receives Notice that Second Indication for AMITIZA for Opioid-Induced Constipation Is Not Approved by Medicines and Healthcare Products Regulatory Agency in U.K.Printer Friendly Version
03/05/14Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2014 ROTH ConferencePrinter Friendly Version
03/04/14Sucampo and National Cherry Blossom Festival Announce Sucampo as Host and 'Step Into Spring' Program Sponsor for 2014Printer Friendly Version
02/26/14Sucampo Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2013 Financial and Operating ResultsPrinter Friendly Version
02/12/14Sucampo Pharmaceuticals Announces Fourth Quarter and Full Year 2013 Results and Operating Highlights Teleconference and WebcastPrinter Friendly Version
02/10/14Sucampo Names Peter Greenleaf Chief Executive OfficerPrinter Friendly Version
02/06/14All Physicians in Switzerland Are Now Able to Prescribe Sucampo's AMITIZA(R) for Chronic Idiopathic ConstipationPrinter Friendly Version
02/05/14Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2014 Leerink Global Healthcare ConferencePrinter Friendly Version